A Randomized Phase ll Study Evaluating the Efficacy and Safety of Combination Therapy of Daunorubicin, Cytarabine Liposomes and Venetoclax Versus Combination Therapy of Azacitidine and Venetoclax in Newly Diagnosed AML Patients Not Eligible for Intensive Chemotherapy
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Cytarabine/daunorubicin (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 20 Jan 2025 New trial record